Pancreatic Cancer Research

ResearcherVita-Salute San Raffaele UniversityActive in the last 2 years

Giulia Orsi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8458-4394; OpenAlex author ID A5020381243. Sources: OpenAlex.

Their work

Papers
40 (first author 7, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
114
Papers, trials and grants by year

2019: 2 papers · 2020: 1 paper · 2021: 6 papers · 2022: 4 papers · 2023: 7 papers · 2024: 8 papers · 2025: 5 papers · 2026: 7 papers

Papers 40

  1. Impact of nutritional status on chemotherapy delivery and outcomes in advanced pancreatic cancer: A prospective multicenter study. First author DOI 10.1016/j.clnu.2025.106573↗
  2. Pancreatic adenocarcinoma nutritional-clinical index (PANCIN): A novel prognostic tool in advanced pancreatic cancer. Last author DOI 10.1016/j.dld.2026.02.015↗
  3. A robust biomarker combining radiomic and CA19.9 information to predict distant relapse-free survival after radiochemotherapy in pancreatic cancer. Co-author DOI 10.1016/j.dld.2026.09.026↗
  4. Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results f… First author DOI 10.1016/j.eclinm.2026.104190↗
  5. Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.ejca.2026.117033↗
  6. Daraxonrasib in refractory PDAC: A one-eyed king in the land of the blind? Co-author DOI 10.1016/j.medj.2026.101227↗
  7. Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the … Co-author DOI 10.1016/s0140-6736(25)01685-x↗
  8. Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. First author DOI 10.1002/cam4.70364↗
  9. Exploring external validity of chemotherapy for pancreatic ductal adenocarcinoma in real life. Co-author DOI 10.1016/j.dld.2024.06.025↗
  10. Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patients. Co-author DOI 10.1016/j.dld.2025.03.009↗
  11. Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional … Co-author DOI 10.1016/j.esmoop.2024.104001↗
  12. Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03268-5↗
  13. Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ctro.2024.100778↗
  14. Exploring the optimal therapeutic management of stage ypIA pancreatic ductal adenocarcinoma patients in the era of primary chemotherapy. Co-author DOI 10.1016/j.dld.2023.07.006↗
  15. Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.dld.2023.07.033↗
  16. Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients. Co-author DOI 10.1016/j.ejca.2024.114226↗
  17. A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing germline BRCA or other DNA damage repair system variants. Co-author DOI 10.1016/j.pan.2024.09.006↗
  18. Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrence. Co-author DOI 10.1016/j.surg.2024.07.026↗
  19. Isolated lung metastases from pancreatic ductal adenocarcinoma (PDAC): Diagnostic and therapeutic challenges of a different disease. Co-author DOI 10.1053/j.seminoncol.2024.04.001↗
  20. Cell Membrane Fatty Acids and PIPs Modulate the Etiology of Pancreatic Cancer by Regulating AKT. Co-author DOI 10.3390/nu17010150↗
  21. Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA… First author DOI 10.1007/s00280-023-04585-w↗
  22. The Role of Neoadjuvant FOLFIRINOX in Borderline Resectable Pancreatic Cancer: A Network Meta-Analysis. Co-author DOI 10.1007/s12029-023-00923-6↗
  23. Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Samples. Co-author DOI 10.1016/j.cgh.2022.10.014↗
  24. The role of biliary events in treatment and survival of patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.dld.2023.04.015↗
  25. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary a… Co-author DOI 10.1016/j.esmoop.2022.100777↗
  26. Lessons and open questions in borderline resectable pancreatic cancer. First author DOI 10.1016/s2468-1253(22)00393-4↗
  27. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). Co-author DOI 10.1038/s41416-022-02086-w↗
  28. Is the Delphi's Oracle Pertinent to Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma? Last author DOI 10.1001/jamaoncol.2022.4673↗
  29. Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1016/j.ctrv.2022.102357↗
  30. Pancreatic cancer: still a cold case? First author DOI 10.1016/s1470-2045(22)00394-1↗
  31. The impact of nutritional status on pancreatic cancer therapy. Co-author DOI 10.1080/14737140.2022.2026771↗
  32. Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients. Co-author DOI 10.1007/s00280-020-04190-1↗
  33. Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants. Co-author DOI 10.1016/j.ctrv.2021.102262↗
  34. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. Co-author DOI 10.1016/j.esmoop.2020.100032↗
  35. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter surve… Co-author DOI 10.1016/j.esmoop.2021.100238↗
  36. Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus. Co-author DOI 10.1177/0300891620976945↗
  37. Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.688889↗
  38. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00280-020-04047-7↗
  39. Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. Co-author DOI 10.1038/s41598-018-37433-6↗
  40. MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma. Co-author DOI 10.7150/thno.27576↗

Closest collaborators

The 25 strongest of 114 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michele Reni · 34 shared papers, 2020–2026 · strength 6.71
  2. Marina Macchini · 29 shared papers, 2020–2026 · strength 5.06
  3. Massimo Falconi · 16 shared papers, 2020–2026 · strength 2.86
  4. Stefano Cascinu · 15 shared papers, 2019–2025 · strength 2.14
  5. Umberto Peretti · 14 shared papers, 2020–2025 · strength 2.05
  6. Catia Carconi · 8 shared papers, 2024–2026 · strength 1.64
  7. Michèle Milella · 10 shared papers, 2021–2026 · strength 1.55
  8. Letizia Procaccio · 8 shared papers, 2023–2026 · strength 1.46
  9. Ilario Giovanni Rapposelli · 9 shared papers, 2021–2026 · strength 1.45
  10. Gabriele Capurso · 8 shared papers, 2021–2026 · strength 1.42
  11. Domenico Tamburrino · 8 shared papers, 2020–2026 · strength 1.34
  12. Paolo Giorgio Arcidiacono · 7 shared papers, 2020–2026 · strength 1.18
  13. Silvia Bozzarelli · 7 shared papers, 2021–2026 · strength 1.13
  14. Mariacristina Di Marco · 7 shared papers, 2021–2026 · strength 1.11
  15. Mario Scartozzi · 7 shared papers, 2021–2026 · strength 1.07
  16. Giulio Belfiori · 6 shared papers, 2021–2026 · strength 1.05
  17. Diego Palumbo · 5 shared papers, 2022–2026 · strength 1.01
  18. Guido Giordano · 7 shared papers, 2021–2025 · strength 0.95
  19. Sara Lonardi · 5 shared papers, 2023–2026 · strength 0.90
  20. Giampaolo Tortora · 7 shared papers, 2021–2025 · strength 0.86
  21. Stefano Partelli · 4 shared papers, 2023–2026 · strength 0.77
  22. Stefano Crippa · 4 shared papers, 2023–2026 · strength 0.77
  23. Lívia Archibugi · 4 shared papers, 2023–2026 · strength 0.72
  24. Elisa Giommoni · 5 shared papers, 2021–2025 · strength 0.70
  25. Lisa Salvatore · 5 shared papers, 2021–2025 · strength 0.66

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.